trial

Electroconvulsive Therapy in Clozapine Refractory Schizophrenia

NCTId NCT00042224
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 39 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2008-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2000-12
Primary completion
2008-07
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Electroconvulsive Therapy (ECT)Clozapine

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Georgios Petrides, MDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Linked catalysts

1
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia — primary completion2008-07

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE1,PHASE2
Primary Completion Date
2008-07
Status
COMPLETED
relationships
The graph out of here
drug
Electroconvulsive Therapy (ECT)
drug
Clozapine
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Georgios Petrides, MD
person